Midlife vascular risk factors and the risk of Alzheimer's disease: a systematic review and meta-analysis.

BACKGROUND/OBJECTIVE We examine whether midlife vascular risk factors (VRFs) are associated with increased risk of incident Alzheimer's disease (AD) in a systematic review and meta-analysis of published cohort studies. METHODS Original cohort studies were included if they reported adjusted combined odds ratio (COR) and corresponding 95% confidence intervals (CIs) or enough information to quantify the association between risk for AD in late-life and baseline VRFs of midlife. RESULTS There were positive and significant associations between high blood pressure (COR 1.31; 95% CI: 1.01-1.70), hypercholesterolemia (COR 1.72; 95% CI: 1.32-2.24), obesity (COR 1.88; 95% CI: 1.32-2.69), and diabetes mellitus in midlife (COR 1.4; 95% CI: 1.25-1.57). Smoking and hyperhomocysteinemia (although only one high-quality paper) were also associated with an increased risk of AD generally. CONCLUSIONS These results strengthen the epidemiological evidence that VRFs of midlife significantly increase risk for AD.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[3]  D. Perl,et al.  Neuropathology of dementia. , 1986, Neurologic clinics.

[4]  P. Whincup,et al.  ASSOCIATION BETWEEN SERUM ALBUMIN AND MORTALITY FROM CARDIOVASCULAR DISEASE, CANCER, AND OTHER CAUSES , 1989, The Lancet.

[5]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[6]  J. D. L. Torre,et al.  Can disturbed brain microcirculation cause Alzheimer’s disease? , 1993 .

[7]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[8]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[10]  A. Nissinen,et al.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. , 1998, Neuroepidemiology.

[11]  A. Hofman,et al.  Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study , 1998, The Lancet.

[12]  T. Harris,et al.  Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance , 1999, Neurology.

[13]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[14]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[15]  J. C. Torre,et al.  Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer’s pathogenesis , 2000, Neurobiology of Aging.

[16]  R. Havlik,et al.  Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.

[17]  D. Bennett,et al.  Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. , 2001, Archives of neurology.

[18]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[19]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[20]  Lars-Olof Wahlund,et al.  Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment , 2002, BMC neurology.

[21]  D. Royall,et al.  Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.

[22]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[23]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[24]  Sudha Seshadri,et al.  Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. , 2003, Archives of internal medicine.

[25]  Y. Mimori,et al.  Association Between Dementia and Midlife Risk Factors: the Radiation Effects Research Foundation Adult Health Study , 2003, Journal of the American Geriatrics Society.

[26]  D. Foley,et al.  Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study , 2003, Neurobiology of Aging.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  R. Stewart,et al.  A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. , 2005, Archives of neurology.

[29]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[30]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[31]  Don L. Armstrong,et al.  Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease , 2005, Nature Medicine.

[32]  A. Dobson,et al.  Quality of reporting of observational longitudinal research. , 2005, American journal of epidemiology.

[33]  Miles C. Miller,et al.  RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease , 2006, Acta Neuropathologica.

[34]  David A. Bennett,et al.  The Relation of Cigarette Smoking to Incident Alzheimer’s Disease in a Biracial Urban Community Population , 2006, Neuroepidemiology.

[35]  K. Yaffe,et al.  Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.

[36]  G. Frisoni,et al.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment , 2007, Journal of Neurology.

[37]  D. Holtzman,et al.  Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  Qian-Li Xue,et al.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. , 2007, Archives of neurology.

[39]  M. Albert,et al.  Single photon emission computed tomography perfusion differences in mild cognitive impairment , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  Andrew Brooks,et al.  Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype , 2007, Proceedings of the National Academy of Sciences.

[41]  A Hofman,et al.  Relation between smoking and risk of dementia and Alzheimer disease , 2007, Neurology.

[42]  Nancy L. Pedersen,et al.  O1-05-08: Mid- and late-life diabetes in relation to the risk of dementia: A population-based twin study , 2008, Alzheimer's & Dementia.

[43]  Luigi Ferrucci,et al.  Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's disease. , 2008, American journal of epidemiology.

[44]  B. Winblad,et al.  Apolipoprotein E ε4 magnifies lifestyle risks for dementia: a population-based study , 2008, Journal of cellular and molecular medicine.

[45]  Qian-Li Xue,et al.  Change in Blood Pressure and Incident Dementia: A 32-Year Prospective Study , 2009, Hypertension.

[46]  N. Pedersen,et al.  Overweight in midlife and risk of dementia: a 40-year follow-up study , 2009, International Journal of Obesity.

[47]  R. Nelson,et al.  The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. , 2009, Current opinion in investigational drugs.

[48]  Lewis H Kuller,et al.  Midlife and late-life obesity and the risk of dementia: cardiovascular health study. , 2009, Archives of neurology.

[49]  M. Kivipelto,et al.  Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later , 2009, Dementia and Geriatric Cognitive Disorders.

[50]  R. Deane,et al.  SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells , 2009, Nature Cell Biology.

[51]  Berislav V. Zlokovic,et al.  Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging , 2010, Neuron.

[52]  C. Björkelund,et al.  The 32-year relationship between cholesterol and dementia from midlife to late life , 2010, Neurology.

[53]  L. Lannfelt,et al.  Vascular Risk Factors and Dementia: 40-Year Follow-Up of a Population-Based Cohort , 2011, Dementia and Geriatric Cognitive Disorders.

[54]  C. Björkelund,et al.  Midlife homocysteine and late-life dementia in women. A prospective population study , 2011, Neurobiology of Aging.

[55]  Minna Rusanen,et al.  Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. , 2011, Archives of internal medicine.

[56]  K. Anand,et al.  Potential Predictors of Hippocampal Atrophy in Alzheimer’s Disease , 2011, Drugs & aging.

[57]  P. Lee,et al.  Mid-life and late-life vascular risk factors and dementia in Korean men and women. , 2011, Archives of gerontology and geriatrics.

[58]  D. Holtzman,et al.  Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.

[59]  I. Skoog,et al.  Blood Pressure Trajectories From Midlife to Late Life in Relation to Dementia in Women Followed for 37 Years , 2012, Hypertension.

[60]  K. Anand,et al.  Are vascular factors linked to the development of hippocampal atrophy in Alzheimer's disease? , 2012, Journal of Alzheimer's disease : JAD.

[61]  Claire Paquet,et al.  A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease , 2011, European Journal of Human Genetics.

[62]  J. C. de la Torre.  Cardiovascular Risk Factors Promote Brain Hypoperfusion Leading to Cognitive Decline and Dementia , 2012, Cardiovascular psychiatry and neurology.

[63]  Ming-Tsu Tsai,et al.  Risk of Alzheimer’s Disease in Relation to Diabetes: A Population-Based Cohort Study , 2012, Neuroepidemiology.

[64]  J. C. de la Torre.  Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[65]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[66]  L. Tan,et al.  Exploring the value of plasma BIN1 as a potential biomarker for alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[67]  C. Choi,et al.  Two β-strands of RAGE participate in the recognition and transport of amyloid-β peptide across the blood brain barrier. , 2013, Biochemical and biophysical research communications.

[68]  J. C. Torre.  Vascular risk factors: a ticking time bomb to Alzheimer's disease. , 2013 .

[69]  L. Tan,et al.  Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. , 2013, Current Alzheimer research.

[70]  M. Mancuso,et al.  Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. , 2012, Current neurovascular research.

[71]  R. Ryan,et al.  Impact of apolipoprotein E on Alzheimer's disease. , 2013, Current Alzheimer research.

[72]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[73]  E. Jamroz,et al.  Apolipoprotein E genotype and LRP1 polymorphisms in patients with different clinical types of metachromatic leukodystrophy. , 2013, Gene.

[74]  L. Tan,et al.  Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[75]  G. Melacini,et al.  In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin. , 2013, Journal of Alzheimer's disease : JAD.

[76]  L. Tan,et al.  Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer's disease patients , 2014, Neuroscience Letters.

[77]  H. Soares,et al.  Meta-Analysis of Peripheral Blood Apolipoprotein E Levels in Alzheimer’s Disease , 2014, PloS one.

[78]  L. Tan,et al.  Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients. , 2013, Journal of Alzheimer's disease : JAD.

[79]  H. Soininen,et al.  Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. , 2013, Journal of Alzheimer's disease : JAD.

[80]  Nan Hu,et al.  Circulating miR-125b as a biomarker of Alzheimer's disease , 2014, Journal of the Neurological Sciences.